The number of volunteers for the Phase I clinical trial is temporarily insufficient, but Sisi's treatment is not restricted by the Phase I clinical trial and can start ahead of schedule.
The biopharmaceutical factory of Ruixing is responsible for producing the biological agent. Their preparation technology is very mature, with both talent and equipment being very well-established. The prepared K biological agent is transported via cold chain vehicles and is very convenient to use, administered directly into Sisi's body through intravenous injection.
After multiple improvements, the current type of virus-like microorganism is very safe, with no adverse reactions upon injection, resembling a common antibiotic injection. In rare cases, a low fever might occur, but this time Sisi didn't even experience a low fever, making it as easy as injecting saline. This low reactivity is a result of many improvements made to the K virus.
